Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2023, Vol. 28 ›› Issue (12): 1415-1421.doi: 10.12092/j.issn.1009-2501.2023.12.012

Previous Articles     Next Articles

Research progress of JAK/STAT signaling pathway in the intervention of diabetic microvascular complications

LI Tao1, YANG Lixia2, GAO Bo3, LI Qin3, SONG Shuang3   

  1. 1Clinical College of Traditional Chinese Medicine, Gansu University of Traditional Chinese Medicine, Lanzhou 730000, Gansu, China; 2Gansu Academy of Traditional Chinese Medicine, Lanzhou 730050, Gansu, China; 3Gansu Health Vocational College, Lanzhou 730207, Gansu, China

  • Received:2023-08-03 Revised:2023-09-21 Online:2023-12-26 Published:2023-12-21

Abstract:

Diabetic microvascular complications are the main reason for the high mortality of diabetic patients. There is still a great shortage of existing therapeutic drugs, so there is an urgent need for more effective new drugs. Janus kinase/signal transducer and activator of transcription (JAK/STAT) is involved in the progression of diabetic microvascular complications, which can be improved by regulating this pathway. Therefore, this article reviews the progress of JAK/STAT in diabetic microvascular complications (diabetic kidney disease, diabetic retinopathy, diabetic peripheral neuropathy), and summarizes the potential drugs that intervene JAK/stat to improve diabetic microvascular complications in recent years from three aspects of therapeutic drugs, preclinical drugs, and traditional Chinese medicine, in order to provide ideas for drug development and treatment of diabetic microvascular complications.

Key words: diabetic microvascular complication, JAk/STAT, traditional Chinese medicine

CLC Number: